IP Library Granted Patent US 7,906,512
Granted Patent B2
US 7,906,512 · App. 12/720,808 · Granted Mar 15, 2011

3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,512
App. No.
12/720,808
Granted
Mar 15, 2011
Kind
B2
Abstract

Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.

Claims (15)

1. A method for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition in a patient which comprises administering to the patient a composition comprising a therapeutically effective amount of a compound of the formula:

wherein:

A=aryl or heteroaryl optionally substituted by F, Cl, Br, C 1 -C 6 alkyl, OR 2 , or OCF 3 ;

R 1 =H, C 1 -C 6 alkyl, heterocyclyl, or (CH 2 ) n —X;

n=1-4;

X=aryl, heteroaryl, OR 5 or NR 3 R 4 ; and

R 2 , R 3 , R 4 , R 5 independently=H or C 1 -C 6 alkyl;

provided that the allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition is selected from the group consisting of nasal allergic disorders; rhinitis; and sinusitis.

2. The method of claim 1 wherein the allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition is an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition of the nose.

3. The method of claim 2 wherein the composition is topically administered to the patient.

4. The method of claim 3 wherein the therapeutically effective amount of the compound is 0.00001-5% (w/v).

5. The method of claim 4 wherein the therapeutically effective amount of the compound is 0.0001-0.5% (w/v).

6. The method of claim 2 wherein the composition is topically administered to the nose of the patient.

7. The method of claim 6 wherein the allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition is a nasal allergic disorder.

8. The method of claim 7 wherein the nasal allergic disorder is selected from the group consisting of allergic rhinitis and sinusitis.

Assignments (2)
MERGER Recorded May 31, 2011
From: ALCON, INC.
To: NOVARTIS AG
Reel/Frame 026376/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2010
From: HELLBERG, MARK R.; MILLER, STEVEN T.; RUSINKO, ANDREW
To: ALCON, INC.
Reel/Frame 024057/0188 →